comparemela.com
  1. Home
  2. Live Updates
  3. Vivo Investor Relations Officer - Breaking News

Latest Breaking News On - Vivo investor relations officer - Page 1 : comparemela.com

Vivos Therapeutics, Inc (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-3.05 EPS, expectations were $-1.9.

United statesScott henryKirk huntsmanJulie gannonVivos therapeutics incDrug administrationExchange commissionVivos instituteVivos therapeuticsCall transcript marchVivos therapeutics fourth quarterFull yearInvestor relationsVivo investor relations officerVivo chairmanChief executive officer

Vivos Therapeutics, Inc (NASDAQ:VVOS) Q1 2023 Earnings Call Transcript

Operator: Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2023 Earnings Conference Call. At this time, participants are in a listen-only mode.

United statesMoss adamsJulie gannonKirk huntsmanScott henryExchange commissionDrug administrationHealth photoVivos therapeutics incStanford universityNational cancer institute on unsplashVivos therapeuticsCall transcript juneVivos therapeutics first quarterInvestor relationsVivo investor relations officer

Vivos Therapeutics, Inc (NASDAQ:VVOS) Q4 2022 Earnings Call Transcript

Operator: Good day, everyone, and welcome to the Vivos Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time participants are in a listen-only mode.

United statesLas vegasScott henryJulie gannonKirk huntsmanBilling intelligence serviceTherapeutic goods administrationBeer companiesBilling intelligence servicesDrug administrationHealth canadaVivos therapeutics incSeattle study clubCanadian ministry of healthExchange commissionVivos institute

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.